Search research articles
Contact Us
Filters
Showing results (101-110 of 123) with videos related to
Page
of 13
Sort By:
Lancet (London, England)
|
April 16, 2019
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
David A Palma, Robert Olson, Stephen Harrow, et al.
The American Journal of Pathology
|
February 6, 2022
Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas
Paul A Christensen, Randall J Olsen, S Wesley Long, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 1, 2022
Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes
Stephen Harrow, David A Palma, Robert Olson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 28, 2025
Multinational validation of distant metastasis velocity as a post-progression prognostic score in patients with oligometastatic cancer treated with metastasis-directed stereotactic body radiotherapy
Jonas Willmann, Sarah Baker, Hanbo Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2020
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
David A Palma, Robert Olson, Stephen Harrow, et al.
BMC Cancer
|
May 7, 2020
Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial
Robert Olson, Lindsay Mathews, Mitchell Liu, et al.
JAMA Oncology
|
September 29, 2022
Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial
Robert Olson, Will Jiang, Mitchell Liu, et al.
The American Journal of Pathology
|
November 14, 2021
Delta Variants of SARS-CoV-2 Cause Significantly Increased Vaccine Breakthrough COVID-19 Cases in Houston, Texas
Paul A Christensen, Randall J Olsen, S Wesley Long, et al.
BMC Cancer
|
August 21, 2019
Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial
David A Palma, Robert Olson, Stephen Harrow, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 11, 2025
Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 Trial
Aiden Kooyman, Jee Suk Chang, Mitchell Liu, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 123) with videos related to
Sort By:
Page
of 13
Lancet (London, England)
|
April 16, 2019
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
David A Palma, Robert Olson, Stephen Harrow, et al.
The American Journal of Pathology
|
February 6, 2022
Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas
Paul A Christensen, Randall J Olsen, S Wesley Long, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 1, 2022
Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes
Stephen Harrow, David A Palma, Robert Olson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 28, 2025
Multinational validation of distant metastasis velocity as a post-progression prognostic score in patients with oligometastatic cancer treated with metastasis-directed stereotactic body radiotherapy
Jonas Willmann, Sarah Baker, Hanbo Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2020
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
David A Palma, Robert Olson, Stephen Harrow, et al.
BMC Cancer
|
May 7, 2020
Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial
Robert Olson, Lindsay Mathews, Mitchell Liu, et al.
JAMA Oncology
|
September 29, 2022
Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial
Robert Olson, Will Jiang, Mitchell Liu, et al.
The American Journal of Pathology
|
November 14, 2021
Delta Variants of SARS-CoV-2 Cause Significantly Increased Vaccine Breakthrough COVID-19 Cases in Houston, Texas
Paul A Christensen, Randall J Olsen, S Wesley Long, et al.
BMC Cancer
|
August 21, 2019
Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial
David A Palma, Robert Olson, Stephen Harrow, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 11, 2025
Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 Trial
Aiden Kooyman, Jee Suk Chang, Mitchell Liu, et al.
Page
of 13